Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
Mark T. Dransfield,Gerard J. Criner,David M. G. Halpin,MeiLan K. Han,Benjamin Hartley,Ravi Kalhan,Peter Lange,David A. Lipson,Fernando J. Martinez,Dawn Midwinter,Dave Singh,Robert Wise,and Ken M. Kunisaki1Lung Health CenterUniversity of Alabama at BirminghamBirmingham AL2Lewis Katz School of Medicine at Temple UniversityPhiladelphia PA3University of Exeter Medical SchoolUniversity of ExeterExeter United Kingdom4University of MichiganAnn Arbor MI5Veramed LtdTwickenham United Kingdom6Division of Pulmonary and Critical Care MedicineNorthwestern University Feinberg School of MedicineChicago IL7University of CopenhagenDenmark8Herlev‐Gentofte HospitalHerlev Denmark9GSKCollegeville PA10Perelman School of MedicineUniversity of PennsylvaniaPhiladelphia PA11New York‐Presbyterian Hospital/Weill Cornell Medical CenterNew York NY12GSKMiddlesex United Kingdom13Centre for Respiratory Medicine and AllergyInstitute of Inflammation and RepairManchester Academic Health Science CentreThe University of ManchesterManchester University NHS Foundation Hospital TrustManchester United Kingdom14Johns Hopkins University School of MedicineBaltimore MD15Minneapolis Veterans Affairs Health Care SystemUniversity of Minnesota Twin Cities Medical SchoolMinneapolis MN
DOI: https://doi.org/10.1161/JAHA.121.024350
2022-09-14
Abstract:Background The association between chronic obstructive pulmonary disease exacerbations and increased cardiovascular event risk has not been adequately studied in a heterogenous population with both low and high cardiovascular risk. Methods and Results This post hoc analysis of the IMPACT (Informing the Pathway of COPD Treatment) trial (N=10 355 symptomatic patients with chronic obstructive pulmonary disease at risk of exacerbations) evaluated time‐dependent risk of cardiovascular adverse events of special interest (CVAESI) following exacerbations and impact of exacerbation history, cardiovascular risk factors, and study treatment on this association. Risk (time‐to‐first) of CVAESI or CVAESI resulting in hospitalization or death was assessed during and 1 to 30, 31 to 90, and 91 to 365 days after resolution of moderate or severe exacerbations. CVAESI risk was compared between the period before and during/after exacerbation. CVAESI risk increased significantly during a moderate (hazard ratio [HR], 2.63 [95% CI, 2.08–3.32]) or severe (HR, 21.84 [95% CI, 17.71–26.93]) exacerbation and remained elevated for 30 days following an exacerbation (moderate: HR, 1.63 [95% CI, 1.28–2.08]; severe: HR, 1.75 [95% CI, 0.99–3.11; nonsignificant]) and decreased over time, returning to baseline by 90 days. Risk of CVAESI resulting in hospitalization or death also increased during an exacerbation (moderate: HR, 2.46 [95% CI, 1.53–3.97]; severe: HR, 41.29 [95% CI, 30.43–56.03]) and decreased in a similar time‐dependent pattern. Results were consistent regardless of exacerbation history, cardiovascular risk at screening, or study treatment. Conclusions Overall risk of cardiovascular events was higher during and in the 30 days following chronic obstructive pulmonary disease exacerbations, even among those with low cardiovascular risk, highlighting the need for exacerbation prevention and vigilance for cardiovascular events following exacerbations. Registration URL: https://clinicaltrials.gov/ct2/show/NCT02164513; Unique identifier: NCT02164513 Nonstandard Abbreviations and Acronyms CVAESI cardiovascular adverse event of special interest FF fluticasone furoate FEV 1 forced expiratory volume in one second UMEC umeclidinium VI vilanterol Clinical Perspective What Is New? The association between chronic obstructive pulmonary disease (COPD) exacerbations and increased cardiovascular event risk has not been fully elucidated. This post hoc analysis of IMPACT (Informing the Pathway of COPD Treatment; n=10 355 patients with COPD at risk for COPD exacerbations) showed that cardiovascular event risk is higher during and in the 30 days following COPD exacerbations, returning to baseline by 90 days. This risk was especially strong during hospitalized exacerbations (hazard ratio, 21.8 [95% CI, 17.7– 26.9]). The association between COPD exacerbations and cardiovascular event risk did not differ by exacerbation history, cardiovascular risk at screening, or study treatment. What Are the Clinical Implications? Providers and patients with COPD should be vigilant for cardiovascular events during and following COPD exacerbations, particularly in exacerbations requiring hospitalization. The natural history of chronic obstructive pulmonary disease (COPD) is characterized by acute exacerbations that, over time, contribute to poorer health outcomes, including reduced lung function 1 , 2 and increased mortality. 3 , 4 Cardiovascular disease (CVD) is a common comorbidity in patients with COPD, affecting between 28% and 70% of patients, 5 and COPD has also been shown to increase the risk of CVD. 5 , 6 Tobacco smoke exposure is a common risk factor for both COPD and CVD (including coronary heart disease, stroke, and vascular disease), 7 and atherosclerosis is exaggerated in smokers with COPD compared with smokers without COPD and nonsmokers with COPD. 8< -Abstract Truncated-